,50 In contrast, PXS-5505 represents a highly selective, orally dosed, small-molecule pan-LOX inhibitor that eliminates off-target effects due to nonspecific processing by other human amine oxidases and has demonstrated safety and tolerability in myelofibrosis (NCT04676529).51 The gene discussed is LOX; the disease is myelofibrosis.